Table 3.

Analysis of variance for determination of the period, sequence, and rifaximin form effects on estimation of C_max, AUC_0–t and AUC_0–∞ after treatment of healthy volunteers with amorphous rifaximin and rifaximin-α at a single dose of 200 mg (n=12) or 400 mg (n=12)

	Period		Sequence		Form
	F	p	F	p	F	p
200 mg
Cmax	1.73	0.2177	0.02	0.8951	36.59	0.0001
AUC0–t	0.28	0.6078	0.26	0.6239	19.52	0.0013
AUC0–∞	2.12	0.1814	0.06	0.8067	15.82	0.0036
400 mg
Cmax	2.70	0.1312	1.55	0.2412	25.30	0.0005
AUC0–t	0.77	0.4020	0.93	0.3564	28.61	0.0003
AUC0–∞	0.53	0.4843	1.01	0.3373	26.59	0.0004

Abbreviations: C_max, highest concentration achieved in plasma; AUC_0–∞, area under drug plasma concentration-time curve from time 0 to infinity; AUC_0–t, AUC from time 0 to time of last quantifiable drug concentration.